Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committee

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 22, Issue 2, 2011, Pages 52-60

  Rouleau, Danielle ^a   Fortin, Claude ^a   Trottier, Benoît ^a,b   Lalonde, Richard ^c   Lapointe, Normand ^d   Côté, Pierre ^a,e,f   Routy, Jean Pierre ^c   Matte, Marie France ^g   Tsarevsky, Irina ^g   Baril, Jean Guy ^a,e,g  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Clinique Medicale l'Actuel   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

^e Clinique Medicale du Quartier Latin   (Canada)

^f Programme National de Mentorat Sur le VIH Sida   (Canada)

^g Ministere de la Sante et des Services Sociaux   (Canada)

Author keywords

Antiretrovirals; HAART; HIV; Practical guide

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LERSIVIRINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; VICRIVIROC; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANADA; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONSULTATION; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG USE; EVIDENCE BASED PRACTICE; HEALTH CARE PERSONNEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MIXED INFECTION; PRACTICE GUIDELINE; PREGNANCY; PROFESSIONAL STANDARD; PROGNOSIS; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT PLANNING; TREATMENT RESPONSE; VIRUS REPLICATION;

EID: 79960019122     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2011/169045     Document Type: Review

References (111)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: U.S. Department of Health and Human Services, 2008.
2. Vernazza P, Hirschel B, Bernasconi E, Flepp M. Les personnes séropositives ne souffrant d'aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle. Bull Med Suisses 2008;89:165-70.
3. Bruneau A, Baril J-G, Bruneau J, et al. Guide pour la prophylaxie après une exposition au VIH, au VHB et au VHC dans un contexte non professionnel. Québec: Ministère de la Santé et des Services sociaux, 2010. (In press)
4. Reynolds S, Makumbi F, Kagaayi J, et al. ART reduced the rate of sexual transmission of HIV among HIV-discordant couples in rural Rakai, Uganda. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 8 to 11, 2009. (Abst)
5. Sullivan P, Kayitenkore K, Chomba E, et al. Reduction of HIV transmission risk and high risk sex while prescribed ART: Results from discordant couples in Rwanda and Zambia. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 8 to 11, 2009. (Abst)
6. Sheth P, Kovacs C, Kemal K, et al. Persistent HIV RNA shedding in semen despite effective ART. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 8 to 11, 2009. (Abst)
7. Marcelin A-G, Tubiana R, Lambert-Niclot S, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 8 to 11, 2009. (Abst)
8. Neely MN, Brening L, Xu J, et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007;44:38-42. (Pubitemid 46052218)
9. U.S. Department of Health and Human Services. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. MMWR 2005;54:1-20.
10. Phillips A, Pezzotti P, CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004;18:51-8. (Pubitemid 38402317)
11. May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: Collaborative analysis of prospective studies. AIDS 2007;21:1185-97. (Pubitemid 46763289)
12. Sterling TR, Chaisson RE, Keruly J, Moore RD. Improved outcomes with earlier initiation of highly active antiretroviral therapy among HIV infected patients who achieve durable virologic suppression: Longer follow-up of an observational cohort study. J Infect Dis 2003;188:1659-65. (Pubitemid 38010676)
13. Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002;360:119-29. (Pubitemid 34786200)
14. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007;44:441-6. (Pubitemid 46147630)
15. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-4. (Pubitemid 28082255)
16. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998;338:853-60. (Pubitemid 28135961)
17. Palella FJ, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003;138:620-6.
18. When To Start Consortium, Sterne JA, May M, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: A collaborative analysis of 18 HIV cohort studies. Lancet 2009;373:1352-63.
19. Jaén Á, Esteve A, Miró JM, et al. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain). J Acquir Immune Defic Syndr 2008;47:212-20. (Pubitemid 351172189)
20. 3 is associated with improved survival. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 8 to 11, 2009. (Abst)
21. Hocqueloux L, Avettand-Fènoël V, Jacquot S, et al. Better HIV-1 DNA depletion and CD4 restoration with HAART initiated at the time of primary HIV infection than with HAART started during chronic HIV infection. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 8 to 11, 2009. (Abst)
22. 3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr 2008;47:27-35.
23. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54. (Pubitemid 27255797)
24. Phair JP, Mellors JW, Detels R, Margolick JB, Muñoz A. Virologic and immunologic values allowing safe deferral of antiretroviral therapy. AIDS 2002;16:2455-9. (Pubitemid 35476884)
25. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-8. (Pubitemid 29458296)
26. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001;183:134-7. (Pubitemid 32043052)
27. Atta MG, Gallant JE, Rahman MH, et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006;21:2809-13. (Pubitemid 44542235)
28. Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005;16:2412-20. (Pubitemid 41725059)
29. Klein M, Baril JG, Charron MA, Fortin C, et al. La prise en charge et le traitement des personnes co-infectées par le virus de l'immunodéficience humaine (VIH) et le virus de l'hépatite B (VHB). Québec: Ministère de la Santé et des Services sociaux, 2010. (In press)
30. Hirsch MS. Initiating therapy: When to start, what to use. J Infect Dis 2008:197:S252-60.
31. D:A:D Study Group, Sabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet 2008;371:1417-26.
32. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;12:F17-24.
33. Lang S, Mary-Krause M, Cotte L, et al. Impact of specific NRTI and PI exposure on the risk of myocardial infarction: A case-control study nested within FHDH ANRS CO4. 16th Conference on Retroviruses and Opportunistic Infections. Montréal, February 8 to 11, 2009. (Abst)
34. Sax P, Tierney C, Collier A, et al. ACTG 5202: Shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part of combination therapy in treatment-naïve subjects with screening HIV RNA ≥100,000 c/mL. XVII International AIDS Conference. Mexico City, August 3 to 8, 2008. (Abst)
35. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009;23:1547-56.
36. Pappa K, Hernandez J, Ha B, et al. Abacavir/lamivudine (ABC/3TC) shows robust virologic responses in ART-naïve patients for baseline (BL) viral loads (VL) of >100,000c/mL and <100,000c/mL by endpoint used in ACTG5202. XVII International AIDS Conference. Mexico City, August 3 to 8, 2008. (Abst)
37. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: No increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009;51:20-8.
38. Benson C, Ribaudo H, Zheng E, et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 8 to 11, 2009. (Abst)
39. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23:1109-18.
40. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-60. (Pubitemid 43113030)
41. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007;44:139-47. (Pubitemid 46292215)
42. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-106. (Pubitemid 351679596)
43. Bartlett JG, Johnson J, Herrera G, et al. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. J Acquir Immune Defic Syndr 2006;43:284-92. (Pubitemid 44674008)
44. Montaner JS, Schutz M, Schwartz R, et al. Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ ritonavir in antiretroviral-naive, HIV-infected patients. MedGenMed 2006;8:36.
45. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir/ritonavir versus lopinavir/ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial. Lancet 2006;368:476-82. (Pubitemid 44160731)
46. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: A noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 2009;50:367-74.
47. Molina J-M, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372:646-55.
48. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008;22:1389-97.
49. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-46. (Pubitemid 34680595)
50. Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009;52:350-6.
51. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806.
52. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: Results from a 48-week, randomized, double-blind study. AIDS 2002;16:1257-63. (Pubitemid 34666660)
53. Squires K, Pozniak AL, Pierone G Jr, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: A randomized trial. Ann Intern Med 2003;139:313-20.
54. Molina J-M, Marcelin AG, Pavie J, et al. Didanosine in HIV-1- infected patients experiencing failure of antiretroviral therapy: A randomized placebo-controlled trial. J Infect Dis 2005;191:830-9.
55. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): A randomized trial. Lancet 2006;367:1981-9. (Pubitemid 43867699)
56. Strategies for Management of AntiRetroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96.
57. Mussini C, Bedini A, Borghi V, et al. CD4 cell-monitored treatment interruption in patients with a CD4 cell count >500 x 106 cells/l. AIDS 2005;19:287-94. (Pubitemid 40396560)
58. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: A controlled, prospective trial. AIDS 2004;18:439-46. (Pubitemid 38365871)
59. Fernández Guerrero ML, Rivas P, Molina M, Garcia R, De Górgolas M. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy. Clin Infect Dis 2005;41:390-4. (Pubitemid 41022119)
60. Taylor S, Fisher M, Jayasuriya A, et al. Kaletra single agent therapy as a universal ART stopping strategy: The STOP 2 study. 10th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, April 15 to 17, 2009. (Abst)
61. Palmisano L, Giuliano M, Bucciardini R, et al. Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: The Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study. J Acquir Immune Defic Syndr 2007;46:39-47 (Pubitemid 47507432)
62. Fox Z, Phillips A, Cohen C, et al. Viral resupression and detection of rug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 2008;22:2279-89.
63. Arnaiz JA, Mallolas J, Podzamczer D, et al. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 2003;17:831-40. (Pubitemid 36547655)
64. Cardiello PG, van Heeswijk RP, Hassink EA, et al. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. J Acquir Immune Defic Syndr 2002;29:464-70. (Pubitemid 34456337)
65. Sprinz E, Neto AJ, Bargman E, et al. Substitution with lopinavir/ ritonavir improves patient-reported outcomes including quality of life in patients who were intolerant to their antiretroviral therapy. HIV Clin Trials 2006;7:291-308. (Pubitemid 46164964)
66. Wood RS, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004;36:684-92. (Pubitemid 38685962)
67. Moyle G, Girard J, Andrade J, et al. Continuation of BID boosted PI vs switch to once-daily ATV/RTV for the management of lipodystrophy: 48 week primary analysis of the 96 week multicenter, open-label, randomized, prospective ReAL study. XVII International AIDS Conference. Mexico City, August 3 to 8, 2008. (Abst)
68. Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002;34:504-10. (Pubitemid 34112272)
69. Maggiolo F, Ripamonti D, Ravasio L, et al. Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection. Clin Infect Dis 2003;37:41-9. (Pubitemid 36836643)
70. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001;27:229-36. (Pubitemid 32661963)
71. Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002;185:1251-60. (Pubitemid 34439132)
72. Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001;15:1517-26. (Pubitemid 32744599)
73. Katlama C, Fenske S, Gazzard B, et al. TRIZAL study: Switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003;4:79-86. (Pubitemid 36582289)
74. Eron J, Andrade J, Zajdenverg R, et al. Switching from stable lopinavir/ritonavir-based to raltegravir-based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 8 to 11, 2009. (Abst)
75. Martínez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003;349:1036-46. (Pubitemid 37087618)
76. De Castro N, Braun J, Charreau I, et al. Switch from enfuvirtide to raltegravir in highly treatment-experienced HIV-1-infected patients: A randomized open-label non-inferiority trial, Easier - ANRS 138. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 8 to 11, 2009. (Abst)
77. Baril J-G, Junod P, Leblanc R, et al. HIV-associated lipodystrophy syndrome: A review of clinical aspects. Can J Infect Dis Med Microbiol 2005;16:233-43. (Pubitemid 41367844)
78. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: A randomized trial. JAMA 2002;288:207-15. (Pubitemid 34755281)
79. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: The results of the TARHEEL study. Clin Infect Dis 2004;38:263-70. (Pubitemid 38113036)
80. Moyle G, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006;20:2043-50. (Pubitemid 44611057)
81. Milinkovic A, Martinez E, López S, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007;12:407-15. (Pubitemid 46787986)
82. Martínez E, Ribera E, Pulido F, et al. Early improvement of limb fat content in patients switching from AZT/3TC to FTC/TDF (TVD): A 24 week interim analysis of the RECOMB trial. XVII International AIDS Conference. Mexico City, August 3 to 8, 2008. (Abst)
83. Fisher M, Moyle GJ, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr 2009;51:562-8.
84. Martínez E, Arranz JA, Podzamczer D, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr 2009;51:290-7.
85. Cooper D, Bloch M, Humphries A, et al. Simplification with fixed-dose tenofovir/emtricitabine or abacavir/lamivudine in adults with suppressed HIV replication: The STEAL study, a randomized, open-label, 96-week, non-inferiority trial. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 8 to 11, 2009. (Abst)
86. Lohse N, Obel N, Kronborg G, et al. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals. AIDS 2005;19:815-22. (Pubitemid 40834752)
87. Moore RD, Keruly JC, Gebo KA, Lucas GM. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr 2005;39:195-8.
88. Albrecht M, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2001;345:398-407. (Pubitemid 32747603)
89. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2304-15. (Pubitemid 37509738)
90. Ruxrungtham K, Pedro RJ, Latiff GH, et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: Study TMC125-C227. HIV Med 2008;9:883-96.
91. Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis 2000;182:1375-84.
92. Hammer SM, Vaida F, Bennett KK, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: A randomized trial. JAMA 2002;288:169-80. (Pubitemid 34755277)
93. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2293-303. (Pubitemid 37509737)
94. Cohen C, Nieto-Cisneros L, Zala C, et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: A randomized multinational trial. Curr Med Res Opin 2005;21:1683-92. (Pubitemid 41505034)
95. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19:685-94. (Pubitemid 40593073)
96. Dragsted UB, Gerstoft J, Youle M, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: The MaxCmin2 trial. Antivir Ther 2005;10:735-43. (Pubitemid 41376853)
97. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: A randomised controlled phase III trial. Lancet 2007;370:49-58.
98. Hicks C, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the randomized evaluation of strategic intervention in multi-drug resistant patients with tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. Lancet 2006;368:466-75. (Pubitemid 44142769)
99. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-78. (Pubitemid 46541620)
100. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29-38. (Pubitemid 47017466)
101. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:39-48. (Pubitemid 47017467)
102. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-41.
103. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54.
104. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359:355-65.
105. Steigbigel R, Cooper D, Eron J, et al. 96-week results from BENCHMRK 1 and 2, phase III studies of raltegravir in patients failing ART with triple-class-resistant HIV. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 8 to 11, 2009. (Abst)
106. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85. (Pubitemid 36618128)
107. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95. (Pubitemid 36618129)
108. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003;349:837-46. (Pubitemid 37025403)
109. Walmsley S, Thorne A, Loutfy M, et al. A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164). J Acquir Immune Defic Syndr 2007;45:418-25. (Pubitemid 47057668)
110. Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study). AIDS 2006;20:795-803. (Pubitemid 43731560)
111. Campbell T, Smeaton L, De Grutolla V, et al. PEARLS (ACTG A5175): A multinational study of didanosine-EC, emtricitabine and atazanavir vs. co-formulated zidovudine/lamivudine and efavirenz for initial treatment of HIV-1 infection. XVII International AIDS Conference. Mexico City, August 3 to 8, 2008. (Abst)